The recent studies have also shown that EP-AD test may also capture the transition from normal aging to mild cognitive impairment, according to the company.
The EP-AD diagnostic also measures small aggregates of Abeta in addition to identification of early-stage patients before they progress into frank AD.
Amorfix president and CEO Robert Gundel said the EP-AD assay service will identify early-stage AD and assist in the development of new compounds to treat AD.
”The EP-AD assay has excellent sensitivity for early-stage diagnosis and enrolment into clinical trials,” Gundel added.
”In addition, this assay has the potential for use as a biomarker to track the effectiveness of treatment to reduce or prevent plaque formation over time."
Amorfix presently provides the diagnostic assay technology to a number of pharmaceutical and biotech companies on a fee-for-service basis.